Mobile

A study comparing the treatment benefits of MPDL32018 used alone and used together with Avastin to Sunitinb. Benefit is being studied in patients who have advanced kidney cancer or kidney cancer which...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003167-58

A study comparing the treatment benefits of MPDL32018 used alone and used together with Avastin to Sunitinb. Benefit is being studied in patients who have advanced kidney cancer or kidney cancer which has spread to other parts of the body and has not been treated before. Acesta este un studiu de faza II, multicentric, randomizat, cu etichetă vizibilă, conceput pentru a estima eficacitatea MPDL3280A + bevacizumab şi a MPDL3280A monoterapie faţă de sunitinib la pacienţii cu RCC confirmat histologic, inoperabil, avansat local sau metastatic, care nu au beneficiat anterior de terapie sistemică nici în contextul adjuvant, nici în cel metastatic

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of MPDL3280A + bevacizumab and MPLD3280A monotherapy compared with sunitinib as measured by progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) via an independent central radiologic review.

Critère d'inclusion

  • ADVANCED RENAL CELL CARCINOMA,CARCINOM CU CELULE RENALE AVANSAT, NETRATAT

Liens